Pay in 4 interest-free payments of $5.22 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Participants in the phase 2 trial lost an average of 7 kg (15 lbs) after 16 weeks, significantly more than the placebo group
In addition to chronic weight management, orforglipron is being studied as a potential treatment for type 2 diabetes, obstructive sleep apnea, osteoarthritis knee pain, hypertension, peripheral artery disease and stress urinary incontinence
In addition to weight management, GLP-1 medications may also help reduce the risk of related conditions such as heart disease, high blood pressure, and elevated cholesterol levels
Selling and distribution expenses rose to 177 million yuan, from 2.39 million yuan a year earlier, while R&D spending reached 206 million yuan
